Arcus Biosciences Leadership Quietly Unloads a Wave of Shares in Coordinated Insider Moves
TipRanks (Thu, 18-Dec 9:04 PM ET)
Arcus Biosciences Amends Loan Facility, Extends Maturity Terms
TipRanks (Thu, 18-Dec 4:35 PM ET)
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Business Wire (Thu, 18-Dec 4:05 PM ET)
Arcus Halts STAR-221 Study, Sharpens Focus on Casdatifan and Next-Gen Inflammation Portfolio
Market Chameleon (Fri, 12-Dec 3:57 AM ET)
Business Wire (Fri, 12-Dec 8:30 AM ET)
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire (Tue, 9-Dec 6:00 PM ET)
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Business Wire (Tue, 18-Nov 4:05 PM ET)
Arcus Biosciences Prices $250 Million Stock Offering—Key Takeaways for Investors
Market Chameleon (Fri, 31-Oct 5:11 AM ET)
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Business Wire (Thu, 30-Oct 11:35 PM ET)
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Business Wire (Thu, 30-Oct 4:01 PM ET)
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Arcus Biosciences trades on the NYSE stock market under the symbol RCUS.
As of December 22, 2025, RCUS stock price climbed to $22.89 with 308,385 million shares trading.
RCUS has a beta of 1.93, meaning it tends to be more sensitive to market movements. RCUS has a correlation of 0.28 to the broad based SPY ETF.
RCUS has a market cap of $2.83 billion. This is considered a Mid Cap stock.
Last quarter Arcus Biosciences reported $26 million in Revenue and -$1.27 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.04.
In the last 3 years, RCUS traded as high as $26.40 and as low as $6.50.
The top ETF exchange traded funds that RCUS belongs to (by Net Assets): IJR, VTI, IWM, XBI, VB.
RCUS has outperformed the market in the last year with a return of +48.1%, while the SPY ETF gained +18.8%. In the last 3 month period, RCUS beat the market returning +84.7%, while SPY returned +3.5%. However, in the most recent 2 weeks RCUS has underperformed the stock market by returning -10.1%, while SPY returned +0.1%.
RCUS support price is $21.15 and resistance is $22.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCUS shares will trade within this expected range on the day.
